Neuropharmacology Flashcards

1
Q

what are the factors that determine the success of a pharmacological treatment

A

primary issues

secondary issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are primary issues

A

Primary issues these are related directly to the disease and its pathology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

give examples of primary issues

A

Understanding of the pathophysiology of the disease – understanding the history of the disease

Choice of the correct treatment target

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are secondary issues

A

Secondary issues these related directly to the therapeutic regime

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

give some examples of secondary issues

A

Ensure that drugs reach the target

Minimise the adverse effects

Manage any potential drug-resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what is the ideal case for treatment and why can that not happen

A
  • a disease would be clearly associated with a specific CNS region
    and a well-defined cellular target
    – but most neurological disease has a much
    higher level of complexity and involves interconnected circuits
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are the types of targets for drugs

A
  • receptor or enzyme
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what are the symptoms of Parkinson’s

A

Tremor, rigidity and slow movement

Slurred speech, affected gait

Irreversible disease progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is the difference between Parkinson’s disease and Parkinsonism

A

Parkinsons disease – it tends to emerge spontaneously, they don’t have a particular cause and just occur as you age

Parkinsoanism – seen in boxers – and reproduces characteristics of Parkinson’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what causes parkinsons disease

A
  • Loss of a specific group of cells in the brain (substantia nigra) which produce dopamine
  • Deficit in dopamine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How do you treat parkinsons

A

Provide the deficient neurotransmitter: dopamine

Provide dopamine precursors: L-Dopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do you make dopamine

A

Dopamine is made from L- tyrosine, then made to L-dopa which is converted to dopamine, the final step is catalyzed by L-arotmatic amino acid decarboxylase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what does the inhibitor of the L-aromatic amino acid decarboxylase do

A

Can administer L dopa with an inhibitor of the enzyme L-arotmatic amino acid decarboxylase but the inhibitor cannot cross the BBB, give L dopa with the inhibitor and this allows you to protect L dopa and convert it only when it gets into the brain and convert it to dopamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what happens if you are given an oral administration of L dopa

A

Systemic oral administration of L-Dopa leads to conversion into dopamine outside the brain - and this can trigger intense vomiting, triggered by peripheral formation of dopamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the solution to L dopa and dopamine not being able to get to the blood Brian barrier

A
  • Provide L-Dopa combined with an inhibitor of the enzyme L-aromatic
    amino acid decarboxylase, WHICH DOES NOT HAVE ACCESS TO THE BRAIN, therefore L-Dopa is converted
    into dopamine ONLY IN THE BRAIN
  • Another solution is to stimulate the dopamine receptors
    directly with dopamine receptor agonists
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are the symptoms of schizophrenia

A
Significant cognitive disruption
Hallucinations, delusions
Paranoid behaviour
Disruption of social contact
Withdrawal from family and friends
17
Q

what is the cause of schizophrenia

A

Hyperactivity in the ventral striatum

Increased release of dopamine

18
Q

what are the treatments of schizophrenia

A
  • dopamine receptor antagonists - antipsychotics of neuroleptic drugs
19
Q

what is the downside of neuroleptic drugs

A

Neuroleptic drugs block dopamine receptors –
BUT THEY ALSO BLOCK OTHER RECEPTORS…
- therefore there lack of specificity causes side effects

20
Q

what are the adverse effects of antipsychotic drugs

A

Rise in prolactin (breast enlargement, amenorrhoea)
Weight gain

General - allergic and toxic reactions

Anticholinergic (antimuscarinic) effects

Postural hypotension

21
Q

what are the symptoms of depression

A
Low mood
Lack of energy
Disrupted sleep
Loss of interest
Tiredness
22
Q

what is the cause of depression

A

Dysfunction in the activity of monoamine systems in the brain
Insufficient level of serotonin and noradrenaline
(monoamine theory)

23
Q

what are the treatment for depression

A

Increase monoaminergic transmission
(e.g. inhibitors of transport/reuptake of monoamines, such as the tricyclic antidepressants or the selective serotonin reuptake inhibitors…)
(blocks the uptake and maintains the neurotransmitter for longer in the synaptic cleft)

24
Q

what do tricyclics do

A

Inhibit reuptake (transport) of monoamines such as serotonin or noradrenaline

BUT ALSO:
Have affinity for histamine H1receptors, muscarinic cholinergic receptors, α1 and α2 adrenoceptors…

25
what are the adverse effects of tricyclics
dry mouth, blurred vision, constipation, urinary retention, fatigue, sedation, weight gain, postural hypotension, dizziness, loss of libido - there is also resistance to treatment in many patients
26
what is the solutions to adverse effects of drugs
reduce the dose or switch to a different drug
27
why do we have resistance to treatment
Body has drug transporter systems which excrete the drug If you have a high expression of these drug transporters this may have an impact on how the patient will respond to the drug
28
when can resistance to treatment develop
The resistance to treatment may be apparent immediately after the onset of the treatment or it can develop after a period of treatment
29
describe how addiction occurs
Gradual onset – drug use becomes the dominant activity
30
what must treatment do for addiction
Help addict overcome symtpoms | Help relieve withdrawl symptoms
31
what does - Ectasy do - heroin do - nicotine do - ketamine do - cocaine do in terms of drug receptor interaction
Ecstasy increases release of monoamines Heroin = Mu opioid receptor agonist Nicotine = nicotinic cholinergic receptor agonist Ketamine = glutamate receptor antagonist Cocaine inhibits uptake of monoamines
32
what are the treatment options for addiction
Provide a drug substitute? Methadone for heroin substitution Provide a vaccine? Antibodies against cocaine Decrease some of the toxicity associated with addiction? Nicotine replacement therapy – patches Aversion therapy? Induce nausea/sickness upon alcohol consumption – block metabolism of alcohol with disulfiram
33
effectiveness of treatment implies...
successful passage of drugs across the blood-brain barrier | - Drug solubility in lipids – essential for crossing membranes
34
why may drug targets in the CNS never be reached
Drug targets in the CNS may be never reached because intrinsic or acquired overexpression of multidrug transporters at the BBB restricts brain uptake of drugs Example of such transporters: the ABC family = ATP-binding cassette transporters Many drugs with effects on the central nervous system are substrates of these transporters, e.g. antiepileptic drugs
35
How do you manage drug resistance
Detection in brain tissue of P-glycoprotein – a drug transporter implicated in drug resistance and drug efflux back from the endothelium into the blood - The solution would be the block of the expression/activity of such transporters Examples of inhibitors of ABC transporters: verapamil, cyclosporine A
36
what are inhibitors of ABC transporters
verapamil | cyclosporine A